Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schaupp, L; Donsa, K; Neubauer, KM; Mader, JK; Aberer, F; Höll, B; Spat, S; Augustin, T; Beck, P; Pieber, TR; Plank, J.
Taking a Closer Look--Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients with Type 2 Diabetes Mellitus Under Basal-Bolus Insulin Therapy.
Diabetes Technol Ther. 2015; 17(9):611-618
Doi: 10.1089/dia.2014.0343
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Schaupp Lukas
- Co-Autor*innen der Med Uni Graz
- Aberer Felix
- Höll Bernhard
- Lichtenegger Katharina
- Mader Julia
- Pieber Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Inpatient glucose management is based on four daily capillary blood glucose (BG) measurements. The aim was to test the capability of continuous glucose monitoring (CGM) for assessing the clinical impact and safety of basal-bolus insulin therapy in non-critically ill hospitalized patients with type 2 diabetes mellitus (T2DM). Eighty-four patients with T2DM (age, 68±10 years; glycosylated hemoglobin, 72±28 mmol/mol; body mass index, 31±7 kg/m(2)) were treated with basal-bolus insulin. CGM was performed with the iPro(®)2 system (Medtronic MiniMed, Northridge, CA) and calibrated retrospectively. A remarkable consistency between CGM and BG measurements and therapy improvement was shown over the study period of 501 patient-days. The number of CGM and BG measurements (CGM/BG) in the range from 3.9-10 mmol/L increased from 67.7%/67.2% (on Day 1) to 77.5%/78.6% (on the last day) (P<0.04). The number of low glycemic episodes (3.3 to <3.9 mmol/L) during nighttime detected by CGM was 15-fold higher, and the number of episodes >13.9 mmol/L detected by CGM during night was 12.5-fold higher than the values from the BG measurements. Ninety-nine percent of data points were in the clinically accurate or acceptable Clarke Error Grid Zones A+B, and the relative numbers of correctly identified episodes of <3.9 and >13.9 mmol/L detected by CGM (sensitivity) were 47.3% and 81.5%, respectively. Our data exhibit a good agreement between overall CGM and BG measurements, but there were a high number of missed hypo- and hyperglycemic episodes with BG measurements, particularly during nighttime. Overall assessment of glycemic control using CGM is feasible, whereas the use of CGM for individualized therapy decisions needs further improvement.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Algorithms -
- Blood Glucose - analysis
- Blood Glucose Self-Monitoring - instrumentation
- Blood Glucose Self-Monitoring - methods
- Diabetes Mellitus, Type 2 - blood
- Diabetes Mellitus, Type 2 - drug therapy
- Female -
- Glycated Hemoglobin A - analysis
- Hospitalization -
- Humans -
- Hypoglycemia - chemically induced
- Hypoglycemic Agents - administration & dosage
- Insulin - administration & dosage
- Male -
- Middle Aged -
- Reproducibility of Results -